Anavex Life Sciences Corp (AVXL)

[falconer66a]

Phase 3 Proof for Blarcamesine’s MOA

The Anavex MOA has yet to be proven in a P3 trial. The MOA is SO DIFFERENT from the prevailing wisdom that it is not taken as seriously as we shareholders do.

Well, the Anavex unique, previously-unknown mechanism of action (MOA), how the company’s molecules induce profound therapeutic results, is actually proven, in both animal models with human CNS genes and diseases, and in real humans. But, no, the results of the big Alzheimer’s Phase 3 clinical trial of blarcamesine have not yet been released.

The issue, of course, is, indeed, that blarcamesine “has yet to be proven,” in the minds of both retail and institutional equity investors. It’s a change minds thing, not a matter of molecular science or the MOA. The MOA is valid and proven. Hesitant, questioning, confused, or objecting minds will be changed when the Phase 3 trial results, later this year, are revealed. They will be as good or better than all of the previous early-phase trials. Only a matter of time, not science or MOA.